The present invention is directed to spiropiperidine compounds of formula and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer’s disease. The frame has a frame central opening configured by an inner perimeter and an outer perimeter and a groove. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. In such a situation, the network address for a device is the seat location of the device.